1. Home
  2. JCE vs NTHI Comparison

JCE vs NTHI Comparison

Compare JCE & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Core Equity Alpha Fund of Beneficial Interest

JCE

Nuveen Core Equity Alpha Fund of Beneficial Interest

N/A

Current Price

$15.47

Market Cap

269.0M

Sector

Finance

ML Signal

N/A

NTHI

NeOnc Technologies Holdings Inc.

N/A

Current Price

$9.76

Market Cap

243.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JCE
NTHI
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
269.0M
243.9M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
JCE
NTHI
Price
$15.47
$9.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.7K
31.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.51
$3.20
52 Week High
$16.31
$16.00

Technical Indicators

Market Signals
Indicator
JCE
NTHI
Relative Strength Index (RSI) 38.14 49.29
Support Level $15.26 $8.29
Resistance Level $15.60 $10.52
Average True Range (ATR) 0.20 0.66
MACD -0.04 -0.06
Stochastic Oscillator 21.58 43.55

Price Performance

Historical Comparison
JCE
NTHI

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).

Share on Social Networks: